Home
/
Vir Biotechnology, Inc.
/
Financials
/
Quarterly
Vir Biotechnology, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Vir Biotechnology, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$240.0K
Nov 5, 2025
Q2
2025
Jun 30, 2025
$1.21M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$3.03M
May 8, 2025
Q3
2025
Sep 30, 2024
$2.38M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$3.08M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$56.38M
May 8, 2025
Q3
2024
Sep 30, 2023
$2.64M
Nov 4, 2024
Q2
2024
Jun 30, 2023
$3.80M
Aug 1, 2024
Q1
2024
Mar 31, 2023
$62.96M
May 3, 2024
Q3
2023
Sep 30, 2022
$374.56M
Nov 3, 2023
Q2
2023
Jun 30, 2022
($40.63M)
Aug 4, 2023
Q1
2023
Mar 31, 2022
$1.23B
May 8, 2023
Q3
2022
Sep 30, 2021
$103.62M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$177.07M
Aug 9, 2022
Q1
2022
Mar 31, 2021
$1.98M
May 5, 2022
Q3
2021
Sep 30, 2020
$1.93M
Nov 4, 2021
Q2
2021
Jun 30, 2020
$66.99M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$5.72M
May 6, 2021
Q3
2020
Sep 30, 2019
$1.40M
Nov 10, 2020
Q2
2020
Jun 30, 2019
$2.05M
Aug 11, 2020
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$240.0K
Nov 5, 2025
Q2
2025
Jun 30, 2025
$1.21M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$3.03M
May 8, 2025
Q3
2025
Sep 30, 2024
$2.38M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$3.08M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$56.38M
May 8, 2025
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($163.14M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($110.96M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($120.97M)
May 8, 2025
Q3
2025
Sep 30, 2024
($213.72M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($138.38M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($65.28M)
May 8, 2025
Q3
2024
Sep 30, 2023
($163.41M)
Nov 4, 2024
Q2
2024
Jun 30, 2023
($194.78M)
Aug 1, 2024
Q1
2024
Mar 31, 2023
($140.96M)
May 3, 2024
Q3
2023
Sep 30, 2022
$175.31M
Nov 3, 2023
Q2
2023
Jun 30, 2022
($76.49M)
Aug 4, 2023
Q1
2023
Mar 31, 2022
$518.62M
May 8, 2023
Q3
2022
Sep 30, 2021
$110.43M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$61.81M
Aug 9, 2022
Q1
2022
Mar 31, 2021
($168.91M)
May 5, 2022
Q3
2021
Sep 30, 2020
($84.61M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($31.17M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($77.24M)
May 6, 2021
Q3
2020
Sep 30, 2019
($48.31M)
Nov 10, 2020
Q2
2020
Jun 30, 2019
($33.93M)
Aug 11, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($173.44M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($118.42M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($139.55M)
May 8, 2025
Q3
2025
Sep 30, 2024
($231.30M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($158.63M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($80.08M)
May 8, 2025
Q3
2024
Sep 30, 2023
($186.73M)
Nov 4, 2024
Q2
2024
Jun 30, 2023
($215.19M)
Aug 1, 2024
Q1
2024
Mar 31, 2023
($143.37M)
May 3, 2024
Q3
2023
Sep 30, 2022
$194.96M
Nov 3, 2023
Q2
2023
Jun 30, 2022
($225.22M)
Aug 4, 2023
Q1
2023
Mar 31, 2022
$1.01B
May 8, 2023
Q3
2022
Sep 30, 2021
($53.39M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
$61.02M
Aug 9, 2022
Q1
2022
Mar 31, 2021
($158.63M)
May 5, 2022
Q3
2021
Sep 30, 2020
($87.62M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($29.05M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($71.91M)
May 6, 2021
Q3
2020
Sep 30, 2019
($47.68M)
Nov 10, 2020
Q2
2020
Jun 30, 2019
($35.77M)
Aug 11, 2020